DAEWOONG CO.,LTD
003090 | KO
Overview
Corporate Details
- ISIN(s):
- KR7003090008
- LEI:
- Country:
- South Korea
- Address:
- 경기 성남시 중원구 상대원동 223-23, 성남시
- Website:
- https://www.daewoong.co.kr
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-15 00:00 |
Regulatory Filings
투자판단관련주요경영사항(자회사의 주요경영사항)
|
Korean | 14.9 KB | ||
| 2025-09-05 00:00 |
Regulatory Filings
투자판단관련주요경영사항(자회사의 주요경영사항)
|
Korean | 9.0 KB | ||
| 2025-08-14 00:00 |
Annual Report
[기재정정]사업보고서 (2024.12)
|
Korean | 3.7 MB | ||
| 2025-08-14 00:00 |
Interim / Quarterly Report
반기보고서 (2025.06)
|
Korean | 4.0 MB | ||
| 2025-07-30 00:00 |
Regulatory Filings
투자판단관련주요경영사항(자회사의 주요경영사항)
|
Korean | 9.5 KB | ||
| 2025-06-02 00:00 |
Governance Information
기업지배구조보고서공시
|
Korean | 708.5 KB | ||
| 2025-05-16 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 25.7 KB | ||
| 2025-05-16 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
|
Korean | 162.0 KB | ||
| 2025-05-16 00:00 |
Major Shareholding Notification
최대주주등소유주식변동신고서
|
Korean | 58.0 KB | ||
| 2025-05-15 00:00 |
Major Shareholding Notification
[기재정정]최대주주등소유주식변동신고서
|
Korean | 54.8 KB | ||
| 2025-05-15 00:00 |
Quarterly Report
분기보고서 (2025.03)
|
Korean | 2.1 MB | ||
| 2025-05-14 00:00 |
Major Shareholding Notification
[기재정정]최대주주등소유주식변동신고서
|
Korean | 60.7 KB | ||
| 2025-04-16 00:00 |
Capital/Financing Update
단기차입금증가결정(자회사의 주요경영사항)
|
Korean | 11.5 KB | ||
| 2025-04-02 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.0 KB | ||
| 2025-04-01 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
|
Korean | 62.4 KB |
Automate Your Workflow. Get a real-time feed of all DAEWOONG CO.,LTD filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for DAEWOONG CO.,LTD
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for DAEWOONG CO.,LTD via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Developing long-acting therapies for rare allergic and immunologic diseases like HAE.
United States of America
ATXS
United States of America
ATXS
Clinical-stage biopharma creating novel psychedelic drugs for mental health disorders.
United States of America
ATAI
United States of America
ATAI
A clinical-stage biopharma developing oral antiviral therapies for viruses like Hepatitis C.
United States of America
AVIR
United States of America
AVIR
Developing small-molecule therapies to slow neurodegeneration in diseases like Alzheimer's.
United States of America
ATHA
United States of America
ATHA
Clinical-stage biopharma developing (Z)-endoxifen for breast cancer treatment and prevention.
United States of America
ATOS
United States of America
ATOS
Developing novel medicines for fibrosis and inflammation using tRNA synthetase biology.
United States of America
ATYR
United States of America
ATYR
Developing virus-like therapies to selectively destroy solid tumors in ocular & urologic oncology.
United States of America
AURA
United States of America
AURA
Biopharma developing therapies for autoimmune and kidney diseases like lupus nephritis.
United States of America
AUPH
United States of America
AUPH
A global producer and seller of medical and recreational cannabis and derivative products.
United States of America
ACB
United States of America
ACB
Develops programmed CAR T-cell therapies for cancer and autoimmune diseases.
United States of America
AUTL
United States of America
AUTL